Capricor Therapeutics (NASDAQ:CAPR) Shares Pass Below 50-Day Moving Average - Here's What Happened

Key Points

• Capricor Therapeutics shares fell below their 50-day moving average of $6.80, trading as low as $6.31 before closing at $6.37.
• The company reported an EPS of -$0.57, which missed analysts' consensus estimates by $0.09.
• Analyst ratings reflect a mixed outlook, with one Strong Buy, seven Buy, and one Sell rating, leading to an average consensus target price of $22.25.

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) passed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $6.80 and traded as low as $6.31. Capricor Therapeutics shares last traded at $6.37, with a volume of 548,281 shares.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Jones Trading lowered their price target on shares of Capricor Therapeutics from $40.00 to $29.00 and set a "buy" rating on the stock in a report on Wednesday, June 25th. Weiss Ratings reissued a "sell (d-)" rating on shares of Capricor Therapeutics in a report on Wednesday, October 8th. Roth Capital reduced their price objective on shares of Capricor Therapeutics from $31.00 to $12.00 and set a "buy" rating for the company in a research report on Monday, July 14th. B. Riley initiated coverage on shares of Capricor Therapeutics in a research report on Thursday, June 26th. They set a "buy" rating and a $21.00 price objective for the company. Finally, Alliance Global Partners restated a "buy" rating on shares of Capricor Therapeutics in a research report on Monday, July 14th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $22.25.

Capricor Therapeutics Stock Down 0.5%

The stock's 50-day simple moving average is $6.80 and its two-hundred day simple moving average is $8.77. The company has a market capitalization of $291.22 million, a price-to-earnings ratio of -3.88 and a beta of 0.68.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its earnings results on Monday, August 11th. The biotechnology company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.09). On average, sell-side analysts forecast that Capricor Therapeutics, Inc. will post -1.21 EPS for the current year.

Institutional Investors Weigh In On Capricor Therapeutics

Hedge funds have recently modified their holdings of the business. Farther Finance Advisors LLC acquired a new stake in shares of Capricor Therapeutics in the third quarter valued at about $28,000. Tower Research Capital LLC TRC raised its position in shares of Capricor Therapeutics by 280.8% in the second quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company's stock valued at $67,000 after buying an additional 4,976 shares during the last quarter. Citizens Financial Group Inc. RI acquired a new stake in shares of Capricor Therapeutics in the first quarter valued at about $95,000. Sheets Smith Investment Management acquired a new stake in shares of Capricor Therapeutics in the third quarter valued at about $107,000. Finally, KLP Kapitalforvaltning AS raised its position in shares of Capricor Therapeutics by 65.2% in the second quarter. KLP Kapitalforvaltning AS now owns 10,900 shares of the biotechnology company's stock valued at $108,000 after buying an additional 4,300 shares during the last quarter. 21.68% of the stock is currently owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.